NCT00215397
Completed
Phase 2
Study in Patients With Asthma
Dey1 site in 1 country16 target enrollmentSeptember 22, 2005
ConditionsAsthma
DrugsFormoterol Fumarate
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- Dey
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- The primary outcome variable is the measure of lung function.
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with a history of asthma
Exclusion Criteria
- •Current asthma exacerbation or recent asthma exacerbation, requiring hospitalization
- •History of smoking
- •Debilitating systemic and/or life-threatening diseases.
Outcomes
Primary Outcomes
The primary outcome variable is the measure of lung function.
Secondary Outcomes
- Secondary outcomes include change in lung function, as well as in vital signs.
- Physical exams, AE reporting, etc.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215358Dey32
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215371Dey32
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215410Dey36
Completed
Phase 3
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe AsthmaAsthmaNCT00393952SkyePharma AG557
Completed
Phase 3
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With AsthmaAsthmaNCT00393991SkyePharma AG475